MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS)

ClinicalTrials.gov ID: NCT04579666

Public ClinicalTrials.gov record NCT04579666. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 5, 2026, 6:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Subjects With Amyotrophic Lateral Sclerosis (ALS)

Study identification

NCT ID: NCT04579666
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 2
Lead sponsor: Apellis Pharmaceuticals, Inc.; Industry
Enrollment: 249 participants

Conditions and interventions

Conditions

Interventions

Pegcetacoplan (APL-2) Drug
Placebo Other

Drug · Other

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Sep 29, 2020
Primary completion: Mar 30, 2023
Completion: Jul 12, 2023
Last update posted: Apr 23, 2025

2020 – 2023

United States locations

U.S. sites: 10
U.S. states: 10
U.S. cities: 10

Facility	City	State	ZIP	Site status
Cedars-Sinai Medical Center	Los Angeles	California	90048	—
University of Colorado	Aurora	Colorado	80045	—
University of South Florida	Tampa	Florida	33612	—
Augusta University	Augusta	Georgia	30912	—
Indiana University	Indianapolis	Indiana	46202	—
Johns Hopkins	Baltimore	Maryland	21205	—
The Berman Center	Minneapolis	Minnesota	55415	—
Hospital for Special Surgery	New York	New York	10021	—
Austin Neuromuscular Center	Austin	Texas	78756	—
University of Vermont Medical Center	Burlington	Vermont	05401	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 50 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04579666, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 23, 2025 · Synced May 5, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04579666 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →